Background Disturbed peripheral negative regulation might contribute to evolution of autoimmune insulitis in type 1 diabetes. This study evaluates the sensitivity of na？ve/effector (Teff) and regulatory T cells (Treg) to activation-induced cell death mediated by Fas cross-linking in NOD and wild-type mice. Principal Findings Both effector (CD25？, FoxP3？) and suppressor (CD25+, FoxP3+) CD4+ T cells are negatively regulated by Fas cross-linking in mixed splenocyte populations of NOD, wild type mice and FoxP3-GFP tranegenes. Proliferation rates and sensitivity to Fas cross-linking are dissociated in Treg cells: fast cycling induced by IL-2 and CD3/CD28 stimulation improve Treg resistance to Fas-ligand (FasL) in both strains. The effector and suppressor CD4+ subsets display balanced sensitivity to negative regulation under baseline conditions, IL-2 and CD3/CD28 stimulation, indicating that stimulation does not perturb immune homeostasis in NOD mice. Effective autocrine apoptosis of diabetogenic cells was evident from delayed onset and reduced incidence of adoptive disease transfer into NOD.SCID by CD4+CD25？ T cells decorated with FasL protein. Treg resistant to Fas-mediated apoptosis retain suppressive activity in vitro. The only detectable differential response was reduced Teff proliferation and upregulation of CD25 following CD3-activation in NOD mice. Conclusion These data document negative regulation of effector and suppressor cells by Fas cross-linking and dissociation between sensitivity to apoptosis and proliferation in stimulated Treg. There is no evidence that perturbed AICD in NOD mice initiates or promotes autoimmune insulitis.
References
[1]
Delovitch TL, Singh B (1997) The non-obese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7: 727–738.
[2]
Kukreja A, Cost G, Marker J, Zhang C, Sun Z, et al. (2002) Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 109: 131–140.
[3]
Waid DM, Vaitaitis GM, Pennock ND, Wagner DH Jr (2008) Disruption of the homeostatic balance between autoaggressive (CD4+CD40+) and regulatory (CD4+CD25+FoxP3+) T cells promotes diabetes. J Leukoc Biol 84: 431–439.
[4]
D'Alise AM, Auyeung V, Feuerer M, Nishio J, Fontenot J, et al. (2008) The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci USA 105: 19857–1962.
[5]
Yarkoni S, Kaminitz A, Sagiv Y, Yaniv I, Askenasy N (2010) Targeted depletion of cells expressing the IL-2 receptor disrupts autoimmunity in prediabetic NOD mice. Diabetologia 53: 356–368.
[6]
Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, et al. (2003) TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9: 1202–1208.
[7]
Berzins SP, Venanzi ES, Benoist C, Mathis D (2003) T-cell compartments of prediabetic NOD mice. Diabetes 52: 327–334.
[8]
Gregg RK, Jain R, Schoenleber SJ, Divekar R, Bell JJ, et al. (2004) A sudden decline in active membranebound TGF-beta impairs both T regulatory cell function and protection against autoimmune diabetes. J Immunol 173: 7308–7316.
[9]
Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, et al. (2005) Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005;54: 92–9.
[10]
Tritt M, Sgouroudis E, d'Hennezel E, Albanese A, Piccirillo CA (2008) Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes 57: 113–123.
[11]
Gregori S, Giarratana N, Smiroldo S, Adorini L (2003) Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol 171: 4040–4047.
[12]
Pop SM, Wong CP, Culton DA, Clarke SH, Tisch R (2005) Single cell analysis shows decreasing FoxP3 and TGFbeta1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes. J Exp Med 201: 1333–1346.
[13]
You S, Belghith M, Cobbold S, Alyanakian MA, Gouarin C, et al. (2005) Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 54: 1415–1422.
[14]
Askenasy N, Yolcu ES, Yaniv I, Shirwan H (2005) Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood 105: 1396–1404.
[15]
Decallonne B, van Etten E, Giulietti A, Casteels K, Overbergh L, et al. (2003) Defect in activation induced cell death in non-obese diabetic (NOD) T lymphocytes. J Autoimmun 20: 219–226.
[16]
Yang W, Hussain S, Mi QS, Santamaria P, Delovitch TL (2004) Perturbed homeostasis of peripheral T cells elicits decreased susceptibility to anti-CD3-induced apoptosis in prediabetic nonobese diabetic mice. J Immunol 173: 4407–4416.
[17]
Arreaza G, Salojin K, Yang W, Zhang J, Gill B, et al. (2003) Deficient activation and resistance to activation-induced apoptosis of CD8+ T cells is associated with defective peripheral tolerance in nonobese diabetic mice. Clin Immunol 107: 103–15.
[18]
Kishimoto H, Sprent J (2001) A defect in central tolerance in NOD mice. Nat Immunol 2: 1025–1031.
[19]
Banz A, Pontoux C, Papiernik M (2002) Modulation of Fas-dependent apoptosis: a dynamic process controlling both the persistence and death of CD4 regulatory T cells and effector T cells. J Immunol 169: 750–757.
[20]
Fritzsching B, Oberle N, Pauly E, Geffers R, Buer J, et al. (2006) Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death. Blood 108: 3371–3378.
[21]
Weber SE, Harbertson J, Godebu E, Mros GA, Padrick RC, et al. (2006) Adaptive islet-specific regulatory CD4 T cells control autoimmune diabetes and mediate the disappearance of pathogenic Th1 cells in vivo. J Immunol 176: 4730–4739.
[22]
Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, et al. (2001) Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 31: 1122–1131.
[23]
Fritzsching B, Oberle N, Eberhardt N, Quick S, Haas J, et al. (2005) In contrast to effector T cells, CD4+CD25+FoxP3+ regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. J Immunol 175: 32–36.
[24]
Mohamood AS, Trujillo CJ, Zheng D, Jie C, Murillo FM, et al. (2006) Gld mutation of Fas ligand increases the frequency and up-regulates cell survival genes in CD25+CD4+ TR cells. Int Immunol 18: 1265–1277.
[25]
Klein L, Khazaie K, von Boehmer H (2003) In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci USA 100: 8886–8891.
[26]
Yarkoni S, Kaminitz A, Sagiv Y, Yaniv I, Askenasy N (2008) Involvement of IL-2 in homeostasis of regulatory T cells: the IL-2 cycle. Bio Essays 30: 875–88.
[27]
Kaminitz A, Askenasy EM, Yaniv I, Stein J, Askenasy N (2010) Apoptosis of purified CD4+ T cell subsets is dominated by cytokine deprivation and absence of other cells in new onset diabetic NOD mice. PLoS One 5: e15684.
[28]
Yolcu ES, Kaminitz A, Ash S, Sagiv Y, Askenasy N, et al. (2008) Apoptosis as a mechanism of T regulatory cell homeostasis and suppression. Immunol Cell Biol 86: 650–658.
[29]
Setoguchi R, Hori S, Takahashi T, Sakaguchi S (2005) Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201: 723–735.
[30]
Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, et al. (2008) Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28: 687–697.
[31]
Lenardo MJ (1991) Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 353: 858–861.
[32]
Kneitz B, Herrmann T, Yonehara S, Schimpl A (1995) Normal clonal expansion but impaired Fas-mediated cell death and anergy induction in interleukin-2-deficient mice. Eur J Immunol 25: 2672–2677.
[33]
Parijs LV, Biuckians A, Ibragimov A, Alt FW, Willerford DM, et al. (1997) Functional responses and apoptosis of CD25 (IL-2Rα)-deficient T cells expressing a transgenic antigen receptor. J Immunol 158: 3738–3745.
[34]
Kaminitz A, Yolcu ES, Stein J, Yaniv I, Shirwan H, et al. (2011) Killer Treg restore immune homeostasis and suppress autoimmune diabetes in prediabetic NOD mice. J Autoimmun. in press.
[35]
Franke DD, Yolcu ES, Alard P, Kosiewicz MM, Shirwan H (2007) A novel multimeric form of FasL modulates the ability of diabetogenic T cells to mediate type 1 diabetes in an adoptive transfer model. Mol Immunol 44: 2884–2892.
[36]
Pearl-Yafe M, Kaminitz A, Yolcu ES, Yaniv I, Stein J, et al. (2007) Pancreatic islets under attack: cellular and molecular effectors. Curr Pharm Des 13: 749–60.
[37]
Giordano C, De Maria R, Stassi G, Todaro M, Richiusa P, et al. (1995) Defective expression of the apoptosis-inducing CD95 (Fas/APO-1) molecule on T and B cells in IDDM. Diabetologia 38: 1449–1454.
[38]
Colucci F, Cilio CM, Lejon K, Gon？alves CP, Bergman ML, et al. (1996) Programmed cell death in the pathogenesis of murine IDDM: resistance to apoptosis induced in lymphocytes by cyclophosphamide. J Autoimmun 9: 271–276.
[39]
Radosevic K, Casteels KM, Mathieu C, van Ewijk W, Drexhage H, et al. (1999) Splenic dendritic cells from the nonobese diabetic mouse induce a prolonged proliferation of syngeneic T cells. A role for an impaired apoptosis of NOD T cells? J Autoimmun 13: 373–382.
[40]
Putnam AL, Vendrame F, Dotta F, Gottlieb PA (2005) CD4+CD25high regulatory T cells in human autoimmune diabetes. J Autoimmun 24: 55–62.
[41]
von Boehmer H (2005) Mechanisms of suppression by suppressor T cells. Nat Immunol 6: 338–344.
[42]
Miyara M, Sakaguchi S (2007) Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 13: 108–116.
[43]
Askenasy N, Kaminitz A, Yarkoni S (2008) Mechanisms of T regulatory cell function. Autoimmun Rev 7: 370–375.
[44]
Shevach EM (2009) Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30: 636–645.
[45]
Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ (2007) CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 8: 1353–1362.
[46]
Pandiyan P, Lenardo MJ (2008) The control of CD4+CD25+Foxp3+ regulatory T cell survival. Biol Direct 3: 6.
[47]
Wang R, Rogers AM, Rush BJ, Russell JH (1996) Induction of sensitivity to activation-induced death in primary CD4+ cells: a role for interleukin-2 in the negative regulation of responses by mature CD4+ T cells. Eur J Immunol 26: 2263–2270.
[48]
Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK (1998) Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8: 615–623.
[49]
de la Rosa M, Rutz S, Dorninger H, Scheffold A (2004) Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol 34: 2480–2488.
[50]
Feinerman O, Jentsch G, Tkach KE, Coward JW, Hathorn MM, et al. (2010) Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response. Mol Syst Biol 6: 437.
[51]
Lan RY, Selmi C, Gershwin ME (2008) The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J Autoimmun 31: 7–12.
[52]
Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, et al. (2000) B7/CD28 co-stimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431–440.
[53]
Arreaza GA, Cameron MJ, Jaramillo A, Gill BM, Hardy D, et al. (1997) Neonatal activation of CD28 signaling overcomes T cell anergy and prevents autoimmune diabetes by an IL-4-dependent mechanism. J Clin Invest 100: 2243–2253.
[54]
Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, et al. (2003) Cutting edge: CD28 controls peripheral homeostasis of CD4+ CD25+ regulatory T cells. J Immunol 171: 3348–3352.
[55]
Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, et al. (2008) The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol 181: 7350–3755.
[56]
Yolcu ES, Askenasy N, Singh NP, Cherradi SE, Shirwan H (2002) Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 17: 795–808.
[57]
Christen U, Darwiche R, Thomas HE, Wolfe T, Rodrigo E, et al. (2004) Virally induced inflammation triggers fratricide of Fas-ligand-expressing beta-cells. Diabetes 53: 591–596.
[58]
Pearl-Yafe M, Yolcu ES, Yaniv I, Stein J, Shirwan H, et al. (2006) The dual role of Fas-ligand as an injury effector and defense strategy in diabetes and islet transplantation. Bioessays 28: 211–222.
[59]
Kaminitz A, Mizrahi K, Yaniv I, Farkas DL, Stein J, et al. (2009) Low levels of allogeneic but not syngeneic hematopoietic chimerism reverse autoimmune insulitis in prediabetic NOD mice. J Autoimmun 33: 83–91.
[60]
Kaminitz A, Mizrahi K, Yaniv I, Stein J, Askenasy N (2010) Immunosuppressive therapy exacerbates autoimmunity in NOD mice and diminishes the protective activity of regulatory T cells. J Autoimmun 35: 145–152.
[61]
Li H, Kaufman CL, Boggs SS, Johnson PC, Patrene KD, et al. (1996) Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in non-obese diabetic (NOD) mice. J Immunol 156: 380–388.
[62]
Beilhack GF, Scheffold YC, Weissman IL, Taylor C, Jerabek L, et al. (2003) Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. Diabetes 52: 59–68.
[63]
Askenasy EM, Askenasy N, Askenasy JJ (2010) Does lymphopenia preclude restoration of immune homeostasis? The particular case of type 1 diabetes. Autoimmun Rev 9: 687–690.
[64]
Yaniv I, Ash S, Farkas DL, Askenasy N, Stein J (2009) Consideration of strategies for hematopoietic cell transplantation. J Autoimmun 33: 255–259.
Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Yaniv I, et al. (2007) Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions. Stem Cells 25: 1448–1455.
